Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010

详细信息    查看全文

• 作者：Camelia Savulescu (1) (2)
  Silvia Jiménez-Jorge (1) (12)
  Salvador de Mateo (1) (12)
  Francisco Pozo (3)
  Inmaculada Casas (3)
  Pilar Pérez Bre?a (3)
  Antonia Galmés (4)
  Juana M Vanrell (4)
  Carolina Rodriguez (5)
  Tomas Vega (5)
  Ana Martinez (6)
  Nuria Torner (12) (6)
  Julián M Ramos (7)
  Maria C Serrano (7)
  Jesús Castilla (12) (8)
  Manuel García Cenoz (12) (8)
  Jone M Altzibar (12) (9)
  Jose M Arteagoitia (10)
  Carmen Qui?ones (11)
  Milagros Perucha (11)
  Amparo Larrauri (1) (12)
  
• 刊名：BMC Public Health
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：11
• 期：1
• 全文大小：188KB
• 参考文献：1. Surveillance Group for New Influenza A(H1N1) Virus Investigation and Control in Spain: New influenza A(H1N1) virus infections in Spain, April-May 2009. [http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19209] / Euro Surveill 2009., 14: pii = 19209
  2. Snacken R, Manuguerra JC, Taylor P: European Influenza Surveillance Scheme on the Internet. / Methods Inf Med 1998, 37:266-0.
  3. Larrauri A, De Mateo S: Characterisation of swabbing for virological analysis in the Spanish Influenza Sentinel Surveillance System during four influenza seasons in the period 2002-006. [http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=706] / Euro Surveill 2007., 12: pii = 706
  4. European Centre for Disease Prevention and Control (ECDC): European Influenza Surveillance Network (EISN). [me.aspx" class="a-plus-plus">http://ecdc.europa.eu/en/activities/surveillance/EISN/Pages/home.aspx]
  5. Ministry of Health and Social Policy, Spain: Recommendations for influenza vaccination in the season 2009-0. [msc.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/gripe.htm#prevencion" class="a-plus-plus">http://www.msc.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/gripe.htm#prevencion]
  6. Larrauri A, Savulescu C, Jiménez-Jorge S, Pérez-Bre?a P, Pozo F, Casas I, Ledesma J, de Mateo S, the Spanish Influenza Surveillance System (SISS): Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008- trivalent vaccine against pandemic influenza in Spain. / Gac Sanit 2011,25(1):23-. CrossRef
  7. World Health Organization (WHO): Recommendations for Influenza Vaccines Composition. Northern hemisphere: 2009-010. [mmendations1/en/index1.html" class="a-plus-plus">http://www.who.int/influenza/vaccines/vaccinerecommendations1/en/index1.html]
  8. World Health Organization (WHO): Recommended composition of influenza virus vaccines for use in the 2010 influenza season-full report. [http://www.who.int/csr/don/2009_09_25/en/]
  9. Ministry of Health and Health Policies, Spain: Vaccination campaign for the pandemic influenza virus H1N1 2009-Official recommendations. [mps.gob.es" class="a-plus-plus">http://www.aemps.gob.es]
  10. Valenciano M, Ciancio B, Moren A: Influenza Vaccine Effectiveness Working Group. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States. [mages/dynamic/EE/V13N43/art19015.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V13N43/art19015.pdf] / Euro Surveill 2008, 13:1-.
  11. Savulescu C, Valenciano M, Mateo S, Larrauri A, the cycEVA Study Team: Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network-Pilot case-control studies using different control groups, 2008-009 season, Spain. / Vaccine 2010, 28:2903-7. CrossRef
  12. Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I: Estimation of influenza vaccine effectiveness from routine surveillance data. [m.nih.gov/pmc/articles/PMC2658741/pdf/pone.0005079.pdf" class="a-plus-plus">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658741/pdf/pone.0005079.pdf] / PLoS One 2009, 4:1-. CrossRef
  13. Fleming DM, Andrews NJ, Ellis JS, Bermingham A, Sebastianpillai P, Elliot AJ, Miller E, Zambon M: Estimating Influenza vaccine effectiveness using routinely collected laboratory data. [mj.com/content/64/12/1062.full.pdf" class="a-plus-plus">http://jech.bmj.com/content/64/12/1062.full.pdf] / J Epidemiol Community Health 2010, 64:1062-7. CrossRef
  14. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, Sebastian R, Chong M, Tam T, De Serres G: Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-006 season of dual A and B vaccine mismatch in Canada. / Vaccine 2007, 25:2842-1. CrossRef
  15. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK: Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-005 season to the 2006-007 season. [http://www.journals.uchicago.edu/doi/pdf/10.1086/595861] / J Infect Dis 2009, 199:159-7. CrossRef
  16. Skowronski DM, De Serres G, Dickenson J, Petric M, Mak A, Fonseca K, Kwindt TL, Chan T, Bastien N, Charest H, Li Y: Component-specific effectiveness of the trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-007. [http://www.journals.uchicago.edu/doi/pdf/10.1086/595862] / J Infect Dis 2009, 199:168-9. CrossRef
  17. European Commission: Commission Decision 2009/363/EC of 30 April 2009 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. [http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:110:0058:0059:EN:PDF] / OJ L58. 110, 1.5.208
  18. European Centre for Disease Prevention and Control (ECDC): Protocol for case-control studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States. [http://www.ecdc.europa.eu/en/publications/Publications/0907_TED_Influenza_AH1N1_Measuring_Influenza_Vaccine_Effectiveness_Protocol_Case_Control_Studies.pdf] Technical document
  19. Ministry of Health and Social Policy, Spain: Pandemic vaccination coverage 2009-010. [mspsi.es/profesionales/saludPublica/prevPromocion/vacunaciones/coberturas.htm" class="a-plus-plus">http://www.mspsi.es/profesionales/saludPublica/prevPromocion/vacunaciones/coberturas.htm]
  20. Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns T: Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-010. [http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19561] / Euro Surveill 2010., 15: pii = 19561
  21. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J: Vaccine effectiveness in pandemic influenza-primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. [mono/mon1434.pdf" class="a-plus-plus">http://www.hta.ac.uk/fullmono/mon1434.pdf] / Health Technol Assess 2010, 14:313-6.
  22. Puig-Barberá J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez-Vilar S, Silvestre-Silvestre E, Calvo-Mas C, Safont-Adsuara L, Ruiz-García M, The Members of the Surveillance and Vaccine Evaluation Group during the autumn 2009 H1N1 pandemic wave in Castellón (Spain): Effectiveness of seasonal 2008-009, 2009-010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. / Vaccine 2010, 28:7460-. CrossRef
  23. Hardelid P, Fleming DM, McMenamin J, Andrews N, Robertson C, SebastianPillai P, Ellis J, Carman W, Wreghitt T, Watson JM, Pebody RG: Effectiveness of pandemic and seasonal influenza vaccine in reventing pandemic influenza A (H1N1)2009 infection in England and Scotland 2009-010. [http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19763] / Euro Surveill 2011., 16: pii = 19763
  24. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, Kwindt TL, Tang P, Charest H, Fonseca K, Gubbay JB, Bastien N, Li Y, Petric M: Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. [mj.com/content/342/bmj.c7297" class="a-plus-plus">http://www.bmj.com/content/342/bmj.c7297] / BMJ 2011., 342:
  25. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, Nunes B, Pitigoi D, Larrauri A, Mosnier A, Horvath JK, O'Donnell J, Bella A, Guiomar R, Lupulescu E, Savulescu C, Ciancio BC, Kramarz P, Moren A: Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009-010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. [medicine.org/article/info:doi/10.1371/journal.pmed.1000388" class="a-plus-plus">http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000388] / PLoS Med 2011., 8:
  26. Valenciano M, Kissling E, Ciancio BC, Moren A: Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. / Vaccine 2010, 28:7381-. CrossRef
  27. World Health Organization (WHO), Regional Office for Europe: European Health for All Database. [http://data.euro.who.int/hfadb/] accessed on 22 October 2010
  28. The pre-publication history for this paper can be accessed here:medcentral.com/1471-2458/11/899/prepub" class="a-plus-plus">http://www.biomedcentral.com/1471-2458/11/899/prepub
  
• 作者单位：Camelia Savulescu (1) (2)
  Silvia Jiménez-Jorge (1) (12)
  Salvador de Mateo (1) (12)
  Francisco Pozo (3)
  Inmaculada Casas (3)
  Pilar Pérez Bre?a (3)
  Antonia Galmés (4)
  Juana M Vanrell (4)
  Carolina Rodriguez (5)
  Tomas Vega (5)
  Ana Martinez (6)
  Nuria Torner (12) (6)
  Julián M Ramos (7)
  Maria C Serrano (7)
  Jesús Castilla (12) (8)
  Manuel García Cenoz (12) (8)
  Jone M Altzibar (12) (9)
  Jose M Arteagoitia (10)
  Carmen Qui?ones (11)
  Milagros Perucha (11)
  Amparo Larrauri (1) (12)
  
  1. Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no.5, 28029, Madrid, Spain
  2. EpiConcept, 47, rue de Charenton, 75012, Paris, France
  12. Consortium for Biomedical Research in Epidemiology & Public Health, Institute of Health Carlos III, Kragujevac, Spain
  3. Institute of Health Carlos III, National Centre for Microbiology, National Influenza Centre, 28220, Majadahonda, Madrid, Spain
  4. Service of Epidemiology, General Directorate of Public Health, Baleares, c/Cecilio Metelo 18, 07003, Palma de Mallorca, Spain
  5. Dirección General de Salud Pública e Investigación, Desarrollo e Innovación. Consejería de Sanidad de Castilla y León, Paseo Zorrilla 1, 47071, Valladolid, Spain
  6. Department of Health, Generalitat of Catalonia, C/Roc Boronat 81-95, 08005, Barcelona, Spain
  7. Sub-directorate of Epidemiology, Public Health Directorate, Avda América 2, 06800, Mérida, Badajoz, Spain
  8. Institute of Public Health of Navarra, Leyre 15, 31003, Pamplona, Spain
  9. Sub-directorate of Public Health, Gipuzkoa, Avda Navarra 4, 20013, Donostia-San Sebastián, Spain
  10. Public Health Service, Department of Health, Basque Government, C/Donostia-San Sebastian 1, 01010, Vitoria-Gasteiz, Spain
  11. General Directorate of Public Health and Consumption, Consejería de Salud. La Rioja Government, C/Gran Vía del rey D. Juan Carlos, no 18, 26071, Logro?o, Spain
  
• ISSN：1471-2458

文摘

Background Physicians of the Spanish Influenza Sentinel Surveillance System report and systematically swab patients attended to their practices for influenza-like illness (ILI). Within the surveillance system, some Spanish regions also participated in an observational study aiming at estimating influenza vaccine effectiveness (cycEVA study). During the season 2009-2010, we estimated pandemic influenza vaccine effectiveness using both the influenza surveillance data and the cycEVA study. Methods We conducted two case-control studies using the test-negative design, between weeks 48/2009 and 8/2010 of the pandemic season. The surveillance-based study included all swabbed patients in the sentinel surveillance system. The cycEVA study included swabbed patients from seven Spanish regions. Cases were laboratory-confirmed pandemic influenza A(H1N1)2009. Controls were ILI patients testing negative for any type of influenza. Variables collected in both studies included demographic data, vaccination status, laboratory results, chronic conditions, and pregnancy. Additionally, cycEVA questionnaire collected data on previous influenza vaccination, smoking, functional status, hospitalisations, visits to the general practitioners, and obesity. We used logistic regression to calculate adjusted odds ratios (OR), computing pandemic influenza vaccine effectiveness as (1-OR)*100. Results We included 331 cases and 995 controls in the surveillance-based study and 85 cases and 351 controls in the cycEVA study. We detected nine (2.7%) and two (2.4%) vaccine failures in the surveillance-based and cycEVA studies, respectively. Adjusting for variables collected in surveillance database and swabbing month, pandemic influenza vaccine effectiveness was 62% (95% confidence interval (CI): -5; 87). The cycEVA vaccine effectiveness was 64% (95%CI: -225; 96) when adjusting for common variables with the surveillance system and 75% (95%CI: -293; 98) adjusting for all variables collected. Conclusion Point estimates of the pandemic influenza vaccine effectiveness suggested a protective effect of the pandemic vaccine against laboratory-confirmed influenza A(H1N1)2009 in the season 2009-2010. Both studies were limited by the low vaccine coverage and the late start of the vaccination campaign. Routine influenza surveillance provides reliable estimates and could be used for influenza vaccine effectiveness studies in future seasons taken into account the surveillance system limitations.